Difference between revisions of "Fluvoxamine"
Jump to navigation
Jump to search
(Created page with "{{concept |wikipedia= |image= |constitutes=SSRI, drug |description=An SSRI }}'''Fluvoxamine''' may be of use in treating long Covid. ==Effects== Fluvoxamine can cross the blo...") |
(unstub) |
||
| Line 1: | Line 1: | ||
{{concept | {{concept | ||
| − | |wikipedia= | + | |wikipedia=https://en.wikipedia.org/wiki/Fluvoxamine |
| − | |image= | + | |image=Fluvoxamine 3D 4ENH.png |
|constitutes=SSRI, drug | |constitutes=SSRI, drug | ||
|description=An SSRI | |description=An SSRI | ||
| − | }}'''Fluvoxamine''' may be of use in treating long Covid. | + | }}'''Fluvoxamine''', sold under the brand name Luvox among others, is an [[antidepressant]] of the [[selective serotonin reuptake inhibitor]] (SSRI) class. It may be of use in treating long Covid. |
==Effects== | ==Effects== | ||
Fluvoxamine can cross the blood-brain barrier. | Fluvoxamine can cross the blood-brain barrier. | ||
| − | In 2021, amid the [[COVID-19 pandemic]], several U.S. universities began clinical trials evaluating the effectiveness of fluvoxamine in mitigating the more severe symptoms of [[coronavirus disease 2019]]. Researchers reported that administering fluvoxamine prevented inflammation of the lungs in COVID-19 patients.<ref> | + | In 2021, amid the [[COVID-19 pandemic]], several U.S. universities began clinical trials evaluating the effectiveness of fluvoxamine in mitigating the more severe symptoms of [[coronavirus disease 2019]]. Researchers reported that administering fluvoxamine prevented inflammation of the lungs in COVID-19 patients.<ref>https://www.nbcmiami.com/investigations/national-investigations/ommon-anti-depressant-pill-shows-promise-in-fighting-covid-19/2372954/</ref> |
| − | A double-blind controlled study found that fluvoxamine may prevent clinical deterioration in outpatients with symptomatic [[COVID-19]]. The study had important limitations: it was run fully remotely; it had a small sample size (150) and short follow-up duration (15 days).<ref name="pmid33180097"> | + | A double-blind controlled study found that fluvoxamine may prevent clinical deterioration in outpatients with symptomatic [[COVID-19]]. The study had important limitations: it was run fully remotely; it had a small sample size (150) and short follow-up duration (15 days).<ref name="pmid33180097">Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (December 2020). "Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial". JAMA. 324 (22): 2292–2300. doi:10.1001/jama.2020.22760</ref> The accompanying editorial noted that, although this study is important enough to choose out of more than 10,000 other COVID-19 related submissions, it "presents only preliminary information [and] the findings should be interpreted as only [[Working hypothesis|hypothesis generating]]; they should not be used as the basis for current treatment decisions."<ref name="pmid33180115">Seymour CW, Bauchner H, Golub RM (December 2020). "COVID-19 Infection-Preventing Clinical Deterioration". JAMA. 324 (22): 2300. doi:10.1001/jama.2020.21720</ref> Similarly, the study authors themselves cautioned that "the trial's results should not be treated as a measure of fluvoxamine's effectiveness against COVID-19 but as an encouraging indicator that the drug warrants further testing."<ref name="UVHS-20201114">https://scitechdaily.com/antidepressant-fluvoxamine-may-prevent-covid-19-infections-from-worsening</ref> A prospective [[Open-label trial|open-labelled]] [[cohort study]] showed similar results.<ref name="Seftel-202102">https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab050/6124100</ref> |
| + | |||
| + | Manufacturers include BayPharma, Synthon, and Teva, among others. Luvox was notably used by [[Eric Harris]], one of the [[Columbine]] shooters.<ref>https://www.washingtonpost.com/wp-srv/national/daily/april99/antisocial04299.htm</ref> | ||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
| − | |||
Revision as of 23:04, 21 June 2021
 Fluvoxamine  (SSRI, drug)   | |
|---|---|
 | |
| An SSRI |
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It may be of use in treating long Covid.
Effects
Fluvoxamine can cross the blood-brain barrier.
In 2021, amid the COVID-19 pandemic, several U.S. universities began clinical trials evaluating the effectiveness of fluvoxamine in mitigating the more severe symptoms of coronavirus disease 2019. Researchers reported that administering fluvoxamine prevented inflammation of the lungs in COVID-19 patients.[1]
A double-blind controlled study found that fluvoxamine may prevent clinical deterioration in outpatients with symptomatic COVID-19. The study had important limitations: it was run fully remotely; it had a small sample size (150) and short follow-up duration (15 days).[2] The accompanying editorial noted that, although this study is important enough to choose out of more than 10,000 other COVID-19 related submissions, it "presents only preliminary information [and] the findings should be interpreted as only hypothesis generating; they should not be used as the basis for current treatment decisions."[3] Similarly, the study authors themselves cautioned that "the trial's results should not be treated as a measure of fluvoxamine's effectiveness against COVID-19 but as an encouraging indicator that the drug warrants further testing."[4] A prospective open-labelled cohort study showed similar results.[5]
Manufacturers include BayPharma, Synthon, and Teva, among others. Luvox was notably used by Eric Harris, one of the Columbine shooters.[6]
Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.
References
- ↑ https://www.nbcmiami.com/investigations/national-investigations/ommon-anti-depressant-pill-shows-promise-in-fighting-covid-19/2372954/
- ↑ Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (December 2020). "Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial". JAMA. 324 (22): 2292–2300. doi:10.1001/jama.2020.22760
- ↑ Seymour CW, Bauchner H, Golub RM (December 2020). "COVID-19 Infection-Preventing Clinical Deterioration". JAMA. 324 (22): 2300. doi:10.1001/jama.2020.21720
- ↑ https://scitechdaily.com/antidepressant-fluvoxamine-may-prevent-covid-19-infections-from-worsening
- ↑ https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab050/6124100
- ↑ https://www.washingtonpost.com/wp-srv/national/daily/april99/antisocial04299.htm
